Boston Scientific's Quarterly Earnings Preview: What You Need to Know

Boston Scientific’s quarterly earnings outlook centers on results due Wednesday, July 29, before the opening bell, as the company approaches fiscal 2026 Q2 reporting. The Marlborough, Massachusetts-based medical technology firm, with an estimated $63.4 billion market capitalization, is expected to deliver diluted EPS of $0.83, up 10.7% from $0.75 a year earlier. Wall Street is also looking for full fiscal 2026 diluted EPS of $3.36, a 9.8% year-over-year rise, with 2027 forecast at $3.70. Despite four straight quarters clearing EPS estimates, BSX shares have fallen 58.9% over 52 weeks versus a 20.7% S&P 500 gain. On Wednesday, April 22, the stock jumped nearly 9% after Q1 FY2026 results: revenue rose 11.6% to $5.20 billion and adjusted EPS increased 6.7% to $0.80. For Q2 FY2026, Boston Scientific projects net sales growth of 5.5% to 7.5% reported and 5% to 7% organic, and adjusted EPS of $0.82 to $0.84, while holding a Strong Buy rating with 21 of 29 analysts supporting it.